3,688 Thermo Fisher Scientific Inc. $TMO Shares Acquired by Atwood & Palmer Inc.

Atwood & Palmer Inc. raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 58,434 shares of the medical research company’s stock after buying an additional 3,688 shares during the quarter. Thermo Fisher Scientific comprises about 2.1% of Atwood & Palmer Inc.’s investment portfolio, making the stock its 14th largest holding. Atwood & Palmer Inc.’s holdings in Thermo Fisher Scientific were worth $39,446,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Fenimore Asset Management Inc increased its position in Thermo Fisher Scientific by 781.0% during the 3rd quarter. Fenimore Asset Management Inc now owns 53,830 shares of the medical research company’s stock valued at $36,338,000 after buying an additional 47,720 shares in the last quarter. Artemis Investment Management LLP boosted its holdings in Thermo Fisher Scientific by 105.5% in the third quarter. Artemis Investment Management LLP now owns 84,793 shares of the medical research company’s stock worth $57,240,000 after acquiring an additional 43,523 shares in the last quarter. Titleist Asset Management LLC grew its stake in shares of Thermo Fisher Scientific by 34.3% during the third quarter. Titleist Asset Management LLC now owns 822 shares of the medical research company’s stock worth $555,000 after acquiring an additional 210 shares during the last quarter. Apella Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 12.6% during the third quarter. Apella Capital LLC now owns 1,429 shares of the medical research company’s stock valued at $946,000 after acquiring an additional 160 shares in the last quarter. Finally, Everhart Financial Group Inc. boosted its stake in Thermo Fisher Scientific by 22.0% in the 3rd quarter. Everhart Financial Group Inc. now owns 2,348 shares of the medical research company’s stock worth $1,585,000 after purchasing an additional 424 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of Thermo Fisher Scientific stock traded down $10.43 on Thursday, hitting $651.63. 2,585,462 shares of the company were exchanged, compared to its average volume of 2,253,558. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $694.33. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The stock has a market capitalization of $240.94 billion, a price-to-earnings ratio of 35.05, a price-to-earnings-growth ratio of 2.75 and a beta of 0.87. The company has a 50-day moving average price of $624.23 and a 200 day moving average price of $539.29.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. The firm had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue was up 10.5% compared to the same quarter last year. During the same quarter last year, the business posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on TMO. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Royal Bank Of Canada raised their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a report on Friday, July 24th. Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to an “underperform” rating in a report on Wednesday, September 9th. Piper Sandler initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “overweight” rating for the company. Finally, Evercore set a $570.00 target price on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $635.55.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer directly owned 2,966 shares of the company’s stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at approximately $13,927,815. This trade represents a 1.60% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 73,768 shares of company stock worth $44,122,820. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.